Assessing efficacy and MoA of mono and combo immunotherapies in preclinical humanized models
Sponsor
The breakthrough of immune checkpoint-targeting therapies has unleashed new hopes and successes for cancer therapy. However, subsets of patients remain who do not show robust responses to immunotherapy. To address this hurdle, combination therapies – coupling agents with distinct mechanisms of action (MoA) – appear promising to enhance treatment success against various cancers.
Choosing a preclinical model to profile new therapies is one of the main challenges in the field of immuno-oncology, as they are expected to predict a faithful translation into clinic, along with anticipating efficacy and tolerability of immunotherapies.
Immunocompetent models featuring humanized immune checkpoints enable the assessment of human-targeted therapies in well-established syngeneic tumor models, allowing investigation in a context of fully functional crosstalk between syngeneic tumor, immune and stroma cells. Importantly, while these models enable profiling evaluation of agents directed toward human targets, results still reflect mouse biology. Alternatively, immunodeficient mice reconstituted with a human immune system offer the possibility to investigate the efficacy and MoA of agents directed against human targets, with the advantage of exploring human biology using human tumor cells lines in a mouse model.
This webinar will demonstrate examples of applicability and complementarity of syngeneic and BRGSF-HIS (Human Immune System) models to assess efficacy and MoA of immunotherapies, either in combination with inhibitory immune checkpoints or as monotherapy.
- Immune checkpoint humanized models enable assessment of human-targeted therapies in well-established syngeneic tumor models, enabling investigation in a context with fully functional crosstalk among syngeneic tumor, immune and stroma cells
- BRGSF-HIS mice, which display functional human lymphoid and myeloid compartments, allow a wide therapeutic window and give the possibility to investigate efficacy and MoA of agents directed to human targets
- Immune checkpoint humanized and BRGSF-HIS models are complementary in assessing efficacy and MoA of immunotherapies
SPEAKERS
You might also like
Enhancing CAR-T efficacy for targeting lymphoma and solid tumors
Assessing mRNA stability and integrity using mass photometry
Assessing CAR-T cell therapy in vitro using patient-derived glioblastoma organoids
Controlled human infection models in vaccine development: what’s new in 2025?
